The table below reflects period 2019 - 2022 calendar years for Sanofi's Jevtana (cabazitaxel)
Since then the figures for Q1 and Q2 2023 have been published
Europe sales for half year 2023 is 8 million Euro. If we extrapolate this to estimated full year 2023 it is 16 million Euro
As can be seen in the table below, from a high of 187 million Euro in 2020 to an estimated 16 million this year is a decrease in estimated sales of 171 million Euro (AU$286 million) over this period. Percentage wise it is a 93% loss in Jevtana revenue in Europe over this period
Sanofi are losing a lot of money to generics in Jevtana sales
It makes complete sense to me for Sanofi to be the licensee for Dep Cabazitaxel
Note
Generic competition in Europe began in March 2021 and can be reflected in the Jevtana revenues since then
Column 1 Column 2 Column 3 Column 4 Column 5 1 year row usa world europe 2 2022 83<4.4%> 275<3.2%> 391<20%> 33<70.5%> 3 2021 90<5.8%> 253+6.5% 455<12.3%> 112<40.6%) 4 2020 103+2.9% 246+17.9% 536+12.2% 187+10.6% 5 2019 78+17.7% 212+12.3% 458+11% 168+7%
- Forums
- ASX - By Stock
- SPL
- Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-70
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.90M |
Open | High | Low | Value | Volume |
9.5¢ | 9.9¢ | 9.0¢ | $14.70K | 154.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 63 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 216 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 63 | 0.094 |
3 | 15514 | 0.092 |
2 | 297913 | 0.091 |
1 | 10000 | 0.090 |
1 | 50000 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 2259 | 3 |
0.100 | 73481 | 4 |
0.105 | 20000 | 1 |
0.110 | 39099 | 5 |
0.115 | 98531 | 6 |
Last trade - 14.57pm 01/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online